15 March 2021 | Alvotech announced it has completed a second round of its US$100 million private placement. In the first round, Alvotech raised US$65 million, including investments from Korea’s Shinhan, US’ Baxter Healthcare SA, and Germany’s ATHOS.
15 March 2021 |Korea Biomedical Review reported that Samsung Bioepis has entered an agreement with Yuhan Corp for the commercialisation of Adalloce™ (biosimilar adalimumab) in South Korea. Adalloce™ is marketed in Europe as Imraldi®.
17 March 2021 | Merck announced it has filed a Form 10 registration statement with the US Securities and Exchange Commission in relation to its intended biosimilars and women’s health spinoff, Organon. Merck announced that Organon will function as a standalone, publicly traded company, with separation on track to be completed late in Q2 2021.
17 March 2021 | Reuters reported that Pfizer will stop producing biosimilar products in China and will sell an intended manufacturing site in Hangzhou to WuXi Biologics.
17 March 2021 | The Korea Herald reported that Celltrion’s Herzuma® (biosimilar trastuzumab) reached a 44% market share in Japan last year.